Literature DB >> 10873092

Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.

E Hinoshita1, T Uchiumi, K Taguchi, N Kinukawa, M Tsuneyoshi, Y Maehara, K Sugimachi, M Kuwano.   

Abstract

The expression of ATP-binding cassette superfamily transporter genes, such as P-glycoprotein/multidrug resistance (MDR) 1 and MDR protein (MRP) 1, is often up-regulated in various tumor types and is involved in responses to some anticancer chemotherapeutic agents. Five human MRP subfamily members (MRP2-6) with structural similarities to MRP1 have been identified. The relationships between MRP2-6 mRNA levels and drug resistance are not well understood. Data on 45 patients with colorectal cancer were analyzed. Of the ATP-binding cassette superfamily genes, we asked whether mRNA levels of MDR1, MRP1, MRP2, and MRP3 correlated with drug resistance to anticancer agents. For this analysis, we used quantitative reverse transcription-PCR, and the sensitivity to anticancer agents in surgically resected colon carcinomas was determined using the in vitro succinate dehydrogenase inhibition test. MDR1, MRP1, and MRP3 were highly expressed in normal colorectal mucosa, and the relative mRNA levels of MDR1, MRP1, and MRP3 in cancerous tissues compared with noncancerous tissues were decreased or unchanged. By contrast, MRP2 mRNA expression was low in normal colorectal mucosa and specifically increased in cancer regions compared with noncancerous regions. Of the anticancer agents prescribed for patients with colorectal cancers, including doxorubicin, mitomycin C, cisplatin, 5-fluorouracil, etoposide, and a camptothecin derivative, mRNA expression of MRP2 was significantly associated with resistance to cisplatin. MRP2 may be important for resistance to cisplatin treatment in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873092

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome.

Authors:  Adam Maciejczyk; Ewa Jagoda; Teresa Wysocka; Rafał Matkowski; Balázs Györffy; Hermann Lage; Paweł Surowiak
Journal:  Pathol Oncol Res       Date:  2011-10-11       Impact factor: 3.201

2.  DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.

Authors:  Elisabetta Bigagli; Carlotta De Filippo; Cinzia Castagnini; Simona Toti; Francesco Acquadro; Francesco Giudici; Marilena Fazi; Piero Dolara; Luca Messerini; Francesco Tonelli; Cristina Luceri
Journal:  Cell Oncol (Dordr)       Date:  2016-10-05       Impact factor: 6.730

Review 3.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Authors:  Tao Hu; Zhen Li; Chun-Ying Gao; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

5.  P-Glycoprotein Activity in Steroid-Responsive vs. Steroid-Resistant Nephrotic Syndrome.

Authors:  Hassan S Badr; Mahmoud A El-Hawy; Mohammed A Helwa
Journal:  Indian J Pediatr       Date:  2016-05-19       Impact factor: 1.967

6.  Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas.

Authors:  Takako Nakahara; Toshiyuki Sakaeda; Tsutomu Nakamura; Takao Tamura; Chiharu Nishioka; Nobuo Aoyama; Noboru Okamura; Toshiro Shirakawa; Akinobu Gotoh; Takashi Kamigaki; Masakazu Ohno; Yoshikazu Kuroda; Masafumi Matsuo; Masato Kasuga; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

7.  Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.

Authors:  Elizabeth W LaPensee; Sandy J Schwemberger; Christopher R LaPensee; El Mustapha Bahassi; Scott E Afton; Nira Ben-Jonathan
Journal:  Carcinogenesis       Date:  2009-05-14       Impact factor: 4.944

8.  MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.

Authors:  Ning Sun; Xinchen Sun; Baoan Chen; Hongyan Cheng; Jifeng Feng; Lu Cheng; Zuhong Lu
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-01       Impact factor: 3.333

Review 9.  Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?

Authors:  F Gieseler; P Rudolph; G Kloeppel; U R Foelsch
Journal:  Int J Colorectal Dis       Date:  2003-05-28       Impact factor: 2.571

10.  E-cadherin increasing multidrug resistance protein 1 via hypoxia-inducible factor-1α contributes to multicellular resistance in colorectal cancer.

Authors:  Xi Liang; Xueqing Xu; Fengchao Wang; Ni Li; Jianming He
Journal:  Tumour Biol       Date:  2015-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.